The effectiveness of targeted therapy with bevacizumab combined with chemotherapy for metastatic colorectal cancer
https://doi.org/10.34215/1609-1175-2020-4-55-58
Abstract
Objective: To estimate the effectiveness of the target therapy with bevacizumab combined with chemotherapy for metastatic colorectal cancer.
Methods: Life expectancy of 208 patients having 3rd and 4th stages was retrospectively analyzed. They received different kinds of treatment: FOLFOX, canecitabin with FOLFOX combined with bevacizumab.
Results: Average life expectancy of the patients having 3rd stage of colorectal cancer is 11.4 months of those who applied FOLFOX scheme, and 14.4 months taking “FOLFOX+bevacizumab” scheme. Of those patients having the 4th stage of cancer this combination of chemotherapy and target medicine resulted in an increase in life expectancy for 3.7 months.
Conclusions: Inclusion of bevacizumab in treatment plan of the patients having 3rd and 4th stages of colorectal cancer improves life expectancy indexes of the patients.
About the Authors
A. V. Ovodova
Pacific State Medical University
Russian Federation
Russian Federation
student,
2 Ostryakova Ave., Vladivostok, 690002
Yu. Yu. Petukhova
Pacific State Medical University;
Primorskiy Regional Oncological Dispensary
Russian Federation
Russian Federation
MD, deputy chief physician,
59 Russian St., Vladivostok, 690105
E. V. Eliseeva
Pacific State Medical University
Russian Federation
Russian Federation
MD, PhD, professor, head of the Department of General and Clinical Pharmacology,
2 Ostryakova Ave., Vladivostok, 690002
O. V. Perelomova
Pacific State Medical University
Russian Federation
Russian Federation
senior lecturer, Institute of Fundamental Foundations and Information Technologies in Medicine,
2 Ostryakova Ave., Vladivostok, 690002
References
1. World Health Organization. International Agency for Research on Cancer 2019. GLOBOCAN 2018: Estimated cancer incidence, mortality, and prevalence worldwide in 2018. Cancer fact sheets. URL: https://gco.iarc.fr/today/home (Accessed: 1 June 2019).
2. Sobolevskaya OA, Ponomarev AF, Gavrina SE, Denisenko LS, Shkuratova OK, Rogatkina ES, Ivanov SP. Colorectal cancer in the Primorsky Territory: Problems of diagnosis and treatment. Pacific Medical Journal. 2013;3:80–2 (in Russ).
3. Fedorov VE, Podelyakin KA. Epidemiological aspects of colorectal cancer (review). Medical Almanac. 2017;4:145–6 (in Russ).
4. Khaitov RM, Kadagidze ZG. Immunity and cancer. Moscow: GEOTAR-Media; 2018:139–46 (in Russ.).
5. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–27.
6. Gabrilovich D, Ishida T, Nadaf S, Ohm J, Carbone D. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999;5:2963–70.
7. Tyulyandin SA. First-line immunotherapy in patients with non-small cell lung cancer: Atezolizumab. Oncology News. Russian Society of Clinical Oncology. 2018 (in Russ). URL: https://rosoncoweb.ru/news/oncology/2018/08/27-1/ (Accesseed: 5 September 2019).
8. Wu HC, Li PC. Proteins expressed on tumor endothelial cells as potential targets for anti-angiogenic therapy. J Cancer Mol. 2008;4:17–22.
9. Giantonio BJ. Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression. Nat Rev Clin Oncol. 2009;6:311–2.
10. Fedyanin MYu, Gladkov OA, Gordeev SS, Rykov IV, Tryakin AA. Practical recommendations for the treatment of colorectal cancer and rectosigmoid connection. Malignant tumors. 2018;8(3):289–324 (in Russ.)
11. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer (MCRC). J Clin Oncol. 2007;25(18 Suppl):4028.
12. Kabbinavar F, Irl C, Zurlo A, Hurwitz H. Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. Oncology. 2008;75:215–23.
13. Feliu J, Safont MJ, Salud A, Losa F, García-Girón C, Bosch C, et al. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer. 2010;102 (10):1468–73.
14. Markovich AA, Gorbunova VA. Clinical prospects of capecitabine. Russian Medical Journal. 2006;14:1016–9 (in Russ).
15. Fedyanin MYu, Tryakin AA. Capecitabine and fluorouracil in the treatment of colorectal cancer and gastric cancer: an analysis of direct comparative studies. Farmateka. 2011;17:20–6 (in Russ).
Review
For citations:
Ovodova A.V., Petukhova Yu.Yu., Eliseeva E.V., Perelomova O.V. The effectiveness of targeted therapy with bevacizumab combined with chemotherapy for metastatic colorectal cancer. Pacific Medical Journal. 2020;(4):55-58. (In Russ.) https://doi.org/10.34215/1609-1175-2020-4-55-58
Views:
757
Email this article 